Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 4, 2013, Pages 274-282

  Vallera, Daniel A ^a   Zhang, Bin ^a   Gleason, Michelle K ^a   Oh, Seunguk ^a   Weiner, Louis M ^b   Kaufman, Dan S ^c   Mccullar, Valarie ^a   Miller, Jeffrey S ^a   Verneris, Michael R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ADCC; Anti CD16; Bispecific antibody; Carcinoma; Human NK cells

Indexed keywords

BISPECIFIC ANTIBODY; CD16 ANTIGEN; CELL MARKER; DIPHTHERIA TOXIN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CELL ADHESION MOLECULE; FC RECEPTOR; HYBRID PROTEIN; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOMA CELL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM; DEGRANULATION; DNA SPLICING; FLOW CYTOMETRY; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOMA; MALE; MOLECULAR WEIGHT; NATURAL KILLER CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TARGET CELL; ANTIBODY PRODUCTION; BREAST TUMOR; CARCINOMA; CELL SURVIVAL; COLON TUMOR; DRUG EFFECTS; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; NEOPLASM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; CELL ADHESION MOLECULES; CELL DEGRANULATION; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84877872803     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1329     Document Type: Article

References (40)

1. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417.
2. Litvinov SV, Velders MP, Bakker HA, et al. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437.
3. Litvinov SV, Bakker HA, Gourevitch MM, et al. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994;2:417.
4. Balzar M, Briaire-de Bruijn IH, Rees-Bakker HA, et al. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol 2001;21:2570.
5. Munz M, Baeuerle PA, Gires O. The emerging role of Ep-CAM in cancer and stem cell signaling. Cancer Res 2009;69:5627.
6. Gires O, Klein CA, Baeuerle PA. On the abundance of Ep-CAM on cancer stem cells. Nat Rev Cancer 2009;9:143.
7. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755.
8. Marhaba R, Klingbeil P, Nuebel T, et al. CD44 and EpCAM: Cancer-initiating cell markers. Curr Mol Med 2008;8:784.
9. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818.
10. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-Associated antigen EpCAM. Nat Cell Biol 2009;11:162.
11. Munz M, Kieu C, Mack B, et al. The carcinoma-Associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748.
12. Stoecklein NH, Siegmund A, Scheunemann P, et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006;6:165.
13. Chaudry MA, Sales K, Ruf P, et al. EpCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges. Br J Cancer 2007;96:1013.
14. Stish BJ, Chen H, Shu Y, et al. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007;13:3058.
15. Sears HF, Herlyn D, Steplewski Z, et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 1984;3: 138.
16. Sears HF, Atkinson B, Mattis J, et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982;1:762.
17. Ragnhammar P, Fagerberg J, Frodin JE, et al. Effect of monoclonal antibody 17- 1A and GM-CSF in patients with advanced colorectal carcinoma-longlasting, complete remissions can be induced. Int J Cancer 1993;53:751.
18. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177.
19. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Sevenyear outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788.
20. Goldberg RM. Lessons learned from the edrecolomab story: How a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie 2005;28:311.
21. Fields AL, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracilbased therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27:1941.
22. Schmoll HJ, Arnold D. When wishful thinking leads to a misty-eyed appraisal: The story of the adjuvant colon cancer trials with edrecolomab. J Clin Oncol 2009;27:1926.
23. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44.
24. Stein C, Kellner C, KÜgler M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 2010;148:879.
25. Singer H, Kellner C, Lanig H, et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 2010;33:599.
26. McCall AM, Adams GP, Amoroso AR, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999;36:433.
27. Gleason MK, Lenvik TR, McCullar V, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012;119:3064.
28. Papadakis KA, Prehn JL, Landers C, et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 2004;172:7002.
29. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in βlineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493.
30. Strö hlein M .A, Lordick F, RÜttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: An open-label, multicenter, phase I/II trial. Onkologie 2011;34:101.
31. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011;3:1445.
32. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: Bispecific antibody constructs with unique anti-Tumor activity. Drug Discov Today 2005;10:1237.
33. Cioffi M, Dorado J, Baeuerle P, et al. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012;18:465.
34. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253.
35. Clarke M .F, Dick J .E, Dirks P .B, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339.
36. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15.
37. Fauriat C, Long EO, Ljunggren H-G, et al. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010;115:2167.
38. Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunctional bispecific (alphaCD3 • alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004;25:841.
39. Seimetz D, Lindhofer H, Bokemeyer. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM• anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458.
40. Sebastian M, Kiewe P, Schuette W, et al. Treatment of malignant pleural effusion with a trifunctional antibody Catumaxomab (Removab) (anti-EpCAM x anti-CD3): Results of a phase 1/2 study. J Immunother 2009;32:195.